var data={"title":"Penicillin V potassium (oral): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Penicillin V potassium (oral): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6746?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=penicillin-v-potassium-oral-patient-drug-information\" class=\"drug drug_patient\">see &quot;Penicillin V potassium (oral): Patient drug information&quot;</a> and <a href=\"topic.htm?path=penicillin-v-potassium-oral-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Penicillin V potassium (oral): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207857\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Pen VK;</li>\n      <li>Novo-Pen-VK;</li>\n      <li>Nu-Pen-VK</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207877\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Penicillin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207860\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> Oral: 125 to 500 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Actinomycosis (off-label use):</b> Oral: <b>Note:</b> Duration is dependent upon disease location and patient-specific factors; complicated infections requiring surgical intervention usually initiate IV therapy with penicillin G until disease subsidence followed by long term oral therapy (Hsieh 1993, Sudhakar 2004):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">2 to 4 g/day in divided doses every 6 hours (Smego 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bite wounds (animal) (off-label use):</b> Oral: 500 mg 4 times daily in combination with dicloxacillin (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cutaneous anthrax, community-acquired (off-label use):</b> Oral: 500 mg 4 times daily for 7 to 10 days (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cutaneous erysipeloid (off-label use):</b> Oral: 500 mg 4 times daily for 7 to 10 days (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Erysipelas:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> 125 to 250 mg every 6 to 8 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing:</i> 500 mg 4 times daily (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fusospirochetosis (Vincent infection):</b> Oral: 250 to 500 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pharyngitis (streptococcal):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute treatment, group A streptococci:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer&rsquo;s labeling: <i>Acute treatment, group A streptococci:</i></i> 125 to 250 mg every 6 to 8 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing:</i> 500 mg 2 to 3 times daily for 10 days (Gerber 2009) <b>or</b> 250 mg 4 times daily or 500 mg twice daily for 10 days (Shulman 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic carrier treatment, group A streptococcal:</i> 500 mg 4 times daily (maximum: 2,000 mg daily) for 10 days in combination with oral rifampin (Shulman 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumococcal prophylaxis in hematopoietic cell transplant (off-label use): </b>Oral: 250 to 500 mg twice daily. <b>Note:</b> Use only in areas where incidence of penicillin-resistant <i>S. pneumoniae</i> is low (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis of recurrent rheumatic fever infections:</b> Oral: 250 mg twice daily (Gerber 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection (off-label use):</b> <i>Chronic oral antimicrobial suppression (Enterococcus spp [penicillin-susceptible], streptococci [beta-hemolytic], Cutibacterium spp):</i> Oral: 500 mg 2 to 4 times daily (Osmon 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Streptococcal skin infection (off-label dose):</b> Oral: 250 to 500 mg every 6 hours (IDSA [Stevens 2014])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207870\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=penicillin-v-potassium-oral-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Penicillin V potassium (oral): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b> General dosing, susceptible infections: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;12 years: Mild to moderate infection: Oral: 25 to 75 mg/kg/day in divided doses every 6 to 8 hours (maximum daily dose: 2,000 mg/<b>day</b>) (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer&rsquo;s labeling (fixed dosing):</i> 125 to 500 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing (weight-based):</i> Mild to moderate infection: 25 to 75 mg/kg/day in divided doses every 6 to 8 hours (maximum daily dose: 2,000 mg/<b>day</b> [<i>Red Book</i> (AAP 2015)])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anthrax (cutaneous), community-acquired (off-label use):</b>  Infants, Children, and Adolescents: Oral: 25 to 50 mg/kg/day in divided doses 2 <b>or</b> 4 times daily; maximum single dose: 500 mg (Stevens 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Fusospirochetosis (Vincent infection), mild to moderately severe infections:</b> Children &ge;12 years and Adolescents: Oral: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tonsillopharyngitis; Group A streptococcal infection, treatment and primary prevention of rheumatic fever:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Acute treatment</i> (Gerber 2009; Shulman 2012; WHO 2004):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &le;27 kg: Oral: 250 mg 2 to 3 times daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;27 kg and Adolescents: Oral: 500 mg 2 to 3 times daily for 10 days; in adolescents, 250 mg 4 times daily has also been suggested</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chronic carrier treatment</i> (Group A <i>streptococci</i>) (off-label use): Children and Adolescents: 50 mg/kg/day in 4 divided doses for 10 days in combination with oral rifampin; maximum daily dose: 2,000 mg/<b>day</b> (Shulman 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Recurrent rheumatic fever, prophylaxis </i>(off-label): Children and Adolescents: 250 mg twice daily (Gerber 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumococcal infection prophylaxis for anatomic or functional asplenia (eg, sickle cell disease [SCD]) (off-label use) (AAP 2002;  Kavanagh 2011; NHLBI 2014): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants (as soon as SCD diagnosed or asplenic) and Children &lt;3 years: Oral: 125 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;3 years: Oral: 250 mg twice daily; the decision to discontinue penicillin prophylaxis after 5 years of age in children who have not experienced invasive pneumococcal infection and have received recommended pneumococcal immunizations is patient and clinician dependent</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired; Group A <i>Streptococcus</i>, mild infection or step-down therapy (off-label use):</b> Infants &ge;3 months, Children, and Adolescents: Oral: 50 to 75 mg/kg/day in 3 to 4 divided doses (Bradley 2011); maximum daily dose: 2,000 mg/<b>day</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207861\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207862\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling. Use with caution; excretion is prolonged in patients with renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22154752\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207833\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (100 mL, 200 mL); 250 mg/5 mL (100 mL, 200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207817\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207836\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>Oral:</i> Administer around-the-clock to promote less variation in peak and trough serum levels. Take on an empty stomach 1 hour before or 2 hours after meals, to enhance absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207834\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Fusospirochetosis (Vincent gingivitis and pharyngitis):</i></b> Treatment of fusospirochetosis (Vincent gingivitis and pharyngitis), in conjunction with dental care for infections involving gum tissue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Pneumococcal infections:</i></b> Treatment of mild to moderately severe pneumococcal respiratory tract infections, including otitis media. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Rheumatic fever and/or chorea prophylaxis:</i></b> Prophylaxis (chronic, secondary) of rheumatic fever and/or chorea.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Staphylococcal infections (penicillin G-sensitive):</i></b> Treatment of mild infections of the skin and soft tissues.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Streptococcal infections (without bacteremia):</i></b> Treatment of mild to moderate streptococcal infections of the upper respiratory tract, scarlet fever, and mild erysipelas.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470478\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Actinomycosis; Bite wounds (animal); Chronic antimicrobial suppression of prosthetic joint infection; Cutaneous anthrax; Cutaneous erysipeloid; GAS chronic carrier; Pneumococcal prophylaxis in asplenia/sickle cell; Pneumococcal prophylaxis in hematopoietic cell transplant; Pneumonia, community-acquired (children)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207884\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Penicillin may be confused with penicillamine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Penicillin V potassium may be confused with penicillin G potassium</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207824\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: Gastrointestinal: Melanoglossia, mild diarrhea, nausea, oral candidiasis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%: Acute interstitial nephritis, anaphylaxis, convulsions, exfoliative dermatitis, fever, hemolytic anemia, hypersensitivity reaction, positive direct Coombs test, serum-sickness like reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207839\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to penicillin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207821\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity or history of sensitivity to multiple allergens.). Use with caution in asthmatic patients. If a serious reaction occurs, treatment with supportive care measures and airway protection should be instituted immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy related issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Prolonged use: Extended duration of therapy or use associated with high serum concentrations (eg, in renal insufficiency) may be associated with an increased risk for some adverse reactions (neutropenia, hemolytic anemia, serum sickness).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299843\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OAT3</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207826\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9751&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207852\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases drug absorption rate; decreases drug serum concentration. Management: Take on an empty stomach 1 hour before or 2 hours after meals around-the-clock to promote less variation in peak and trough serum levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5720583\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Penicillin crosses the placenta. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of penicillin V may be altered in the second and third trimester (Heikkil&auml; 1993). If treatment for the management of <i>Bacillus anthracis</i> is needed in pregnant women, other agents are preferred (Meaney-Delman 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207843\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Penicillin V is excreted into breast milk and may be detected in the urine of some breast-feeding infants. Loose stools and rash have been reported in nursing infants (Matheson 1988).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207831\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic renal and hematologic function tests during prolonged therapy; monitor for signs of anaphylaxis during first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207820\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207838\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: 80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as unchanged drug and metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207842\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Penicillin V Potassium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (100 mL): $9.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (100 mL): $10.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Penicillin V Potassium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $76.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $77.77</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207845\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abbocillin VK (AU);</li>\n      <li>Anapenil (MX);</li>\n      <li>Beapen VK (MY);</li>\n      <li>Cilicaine VK (AU, NZ);</li>\n      <li>Cilopen VK (AU);</li>\n      <li>Fenocin (ID);</li>\n      <li>Kaypen (IN);</li>\n      <li>L.P.V. (AU);</li>\n      <li>Len V.K. (ZA);</li>\n      <li>Megacilina Oral (PE);</li>\n      <li>Milcopen (FI);</li>\n      <li>Oracillin VK (ZA);</li>\n      <li>Orapen (ZW);</li>\n      <li>Orvek (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ospa-V (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ospen (AE, AT, EG, FR, JO, KW, LB, MY, QA, SA, SG, UY, VE);</li>\n      <li>P.P.V. (AE);</li>\n      <li>Pen V (HK);</li>\n      <li>Pen Ve Oral (BR);</li>\n      <li>Pen-Rafa V-K (IL);</li>\n      <li>Pen-Vi-K (MX);</li>\n      <li>Penilevel (ES);</li>\n      <li>Penoxil (MY);</li>\n      <li>Pota-Vi-Kin (MX);</li>\n      <li>Prevecilina (CO);</li>\n      <li>Robicillin VK (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Semicillin (TH);</li>\n      <li>Sumapen (PH);</li>\n      <li>V-Cil-K (AE, BB, BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, PR, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);</li>\n      <li>V-Cillin K (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Vikadar (AE, BH, JO, QA, SA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics. Section on Hematology/Oncology Committee on Genetics. Health supervision for children with sickle cell disease. <i>Pediatrics</i>. 2002;109(3):526-535.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/11875155/pubmed\" target=\"_blank\" id=\"11875155\">11875155</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al; Pediatric Infectious Diseases Society; Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>, 2011, 53(7):e25-e76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. <i>Circulation</i>. 2009;119(11):1541-1551.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/19246689/pubmed\" target=\"_blank\" id=\"19246689\">19246689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heikkil&auml; AM, Erkkola RU. The need for adjustment of dosage regimen of penicillin V during pregnancy. <i>Obstet Gynecol.</i> 1993;81(6):919-921.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/8497356/pubmed\" target=\"_blank\" id=\"8497356\">8497356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8339619\"></a>Hsieh MJ, Liu, HP, Chang, JP, Chang CH. Thoracic actinomycosis. <i>Chest</i>. 1993;104(2):366-370.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/8339619/pubmed\" target=\"_blank\" id=\"8339619\">8339619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kavanagh PL, Sprinz PG, Vinci SR, et al. Management of children with sickle cell disease: a comprehensive review of the literature. <i>Pediatrics</i>. 2011;128(6):e1552-1574.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/22123880/pubmed\" target=\"_blank\" id=\"22123880\">22123880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matheson I, Samseth M, L&oslash;berg R, Faegri A, Prentice A. Milk transfer of phenoxymethylpenicillin during puerperal mastitis. <i>Br J Clin Pharmacol.</i> 1988;25(1):33-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/3130891/pubmed\" target=\"_blank\" id=\"3130891\">3130891</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/24457117/pubmed\" target=\"_blank\" id=\"24457117\">24457117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute (NHLBI). Evidence-based management of sickle cell disease: expert panel report, 2014. Bethesda, MD: National Institutes of Health; 2014. <a href=\"http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines\" target=\"_blank\">http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines</a>. Accessed March 19, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Penicillin V potassium [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimberlin DW, Brady MT, Jackson MA, Long SS, eds; Committee on Infectious Diseases; American Academy of Pediatrics. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>, 2012;55(10):e86-e102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/22965026/pubmed\" target=\"_blank\" id=\"22965026\">22965026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9636842\"></a>Smego RA Jr, Foglia G. Actinomycosis.<i> Clin Infect Dis</i>. 1998;26(6):1255-1261; quiz 1262-1263.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/9636842/pubmed\" target=\"_blank\" id=\"9636842\">9636842</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. <i>Clin Infect Dis</i>. 2005;41(10):1373-1406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/16231249/pubmed\" target=\"_blank\" id=\"16231249\">16231249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14727221\"></a>Sudhaker SS, Ross JJ. Short-term treatment of actinomycosis: two cases and a review. <i>Clin Infect Dis</i>. 2004;38(3):444-447.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/14727221/pubmed\" target=\"_blank\" id=\"14727221\">14727221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19747629\"></a>Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and MarrowTransplant Group; et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-238. doi: 10.1016/j.bbmt.2009.06.019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      World Health Organization (WHO). Rheumatic fever and rheumatic heart disease. 2004. Available at http://whqlibdoc.who.int/trs/WHO_TRS_923.pdf14727221</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL and Bergman SA, &ldquo;Antibiotics and Their Use in the Treatment of Orofacial Infections, Part I and Part II,&rdquo; <i>Gen Dent</i>, 1994, 42(5):398-402, 498-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/7489869/pubmed\" target=\"_blank\" id=\"7489869\">7489869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, Bergman SA, Meiller TF, et al, &ldquo;Antibiotics in Treating Oral-Facial Infections of Odontogenic Origin: An Update,&rdquo; <i>Gen Dent</i>, 2001, 49(3):238-40, 242, 244 passim.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-v-potassium-oral-drug-information/abstract-text/12004720 /pubmed\" target=\"_blank\" id=\"12004720 \">12004720 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9751 Version 195.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F207857\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F207877\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F207860\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F207870\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F207861\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F207862\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22154752\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F207833\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F207817\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F207836\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F207834\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470478\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F207884\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F207824\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F207839\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F207821\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299843\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F207826\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F207852\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5720583\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F207843\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F207831\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F207820\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F207838\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F207842\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F207845\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9751|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=penicillin-v-potassium-oral-patient-drug-information\" class=\"drug drug_patient\">Penicillin V potassium (oral): Patient drug information</a></li><li><a href=\"topic.htm?path=penicillin-v-potassium-oral-pediatric-drug-information\" class=\"drug drug_pediatric\">Penicillin V potassium (oral): Pediatric drug information</a></li></ul></div></div>","javascript":null}